



## **Special Track Session 2**

Oncology & Theranostics Committee

**Sunday, October 5, 09:45 – 11:15**

### **Session Title**

**Debate: A Brave New World: Are All PSMA Radiopharmaceuticals Equal?**

### **Moderators**

**Karolien Goffin** (Leuven, Belgium)

**Andrei Iagaru** (Stanford, United States of America)

### **Point of view: PSMA diagnostics: all equal**

**Daniela, Oprea Lager** (Nijmegen, Netherlands)

**Stefano Fanti** (Bologna, Italy)

### **Point of view: PSMA diagnostics: there are differences**

**Irene Burger** (Baden, Switzerland)

**Matthias Eiber** (Munich, Germany)

## **Educational Objectives**

1. Understand the principles of PSMA-targeting in prostate cancer.
2. Compare and contrast the characteristics of different PSMA-targeting diagnostic agents.
3. Compare and contrast the characteristics of different PSMA-targeting therapeutic agents.
4. Discuss the current and potential applications of these radiopharmaceuticals in the management of prostate cancer.
5. Analyse the factors that might influence the choice of a specific compound for a given clinical scenario.

## **Summary**

This session aims to enhance participants' understanding of the biological, clinical, and practical aspects of PSMA-targeted radiopharmaceuticals. Attendees will explore the similarities and differences between diagnostic and therapeutic agents, focusing on their mechanisms, pharmacokinetics, and clinical indications. The debate will also cover efficacy, safety, and toxicity profiles across various compounds, particularly comparing beta- and alpha-emitting therapies. Broader considerations, including cost, access, and global health equity, could also be discussed. Participants can critically evaluate evidence, articulate well-informed positions, and engage in collaborative scientific debate.

## **Key Words**

PSMA; theranostics; PET; RLT